Intranasally Administered Adjunctive Dexmedetomidine Reduces Perioperative Anesthetic Requirements in General Anesthesia

Xiang Wu¹, Li-Hua Hang², Hong Wang², Dong-Hua Shao², Yi-Guo Xu¹, Wei Cui¹, and Zheng Chen²

¹Department of Anesthesiology, The Affiliated Hospital of School of Medicine of Ningbo University, Ningbo, Zhejiang; ²Department of Anesthesiology, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

**Purpose:** Intranasal dexmedetomidine is an effective sedative for premedication and is regularly used to reduce preoperative tension and anxiety in children. This study aimed to assess the effect of intranasally adjunctive dexmedetomidine on perioperative sedative and analgesic requirements in adults.

**Materials and Methods:** Patients were randomly divided into four groups to receive preoperative administration of saline, intranasal dexmedetomidine 1 μg/kg and 2 μg/kg, and intravenous dexmedetomidine 1 μg/kg, respectively. Propofol and remifentanil were target-controlled infused to maintain intraoperative bispectral index at 45–55 and blood pressure at baseline value±20%. Sufentanil was administered to maintain postoperative visual analogue scale ≤3. Perioperative anesthetics requirements were compared using nonparametric tests.

**Results:** Intranasal dexmedetomidine significantly attenuated propofol requirements for anesthesia induction and maintenance in a dose-dependent manner. Patients given intranasal dexmedetomidine 2 μg/kg required less remifentanil for anesthesia maintenance. The first postoperative request for sufentanil analgesia was delayed in patients given intranasal dexmedetomidine 2 μg/kg. The anesthetics-sparing effect of intranasal dexmedetomidine was significantly weaker than intravenous dexmedetomidine at the same dose of 1 μg/kg. The incidences of adverse events, including hemodynamic instability and delayed recovery, were comparable with and without intranasal dexmedetomidine.

**Conclusion:** Intranasal administration of dexmedetomidine can reduce perioperative anesthetic requirements, and a dose of dexmedetomidine 2 μg/kg produces a better effect in adults. The anesthetics-sparing effect of intranasal dexmedetomidine 1 μg/kg is less than that with the same intravenous dose of dexmedetomidine.

**Key Words:** Dexmedetomidine; administration, intranasal; anesthetics, intravenous
requirements in general anesthesia remains unknown. It was reported that the sedative onset time of intranasal dexmedetomidine is 45–60 min with a peak effect at 90–105 min in adults.\(^9\) We, therefore, hypothesized that intranasal dexmedetomidine could reduce anesthetic amounts used in operations lasting between 1–2 h. In addition, we aimed to compare the effects of dexmedetomidine administered intranasally and intravenously at equal preoperative doses on perioperative anesthetics requirements in adults.

**MATERIALS AND METHODS**

The study was approved by the ethics committee of the Affiliated People’s Hospital of Jiangsu University and registered at www.chictr.org (ChiCTR-IOC-14005537). With written informed consent, patients scheduled for elective hysterectomy were recruited. Eligible participants were 40 to 55 years old with ASA physical status I. Exclusion criteria were as follows: 1) body mass index ≥30 kg/m\(^2\); 2) history of nasal operation and nasal diseases, including rhinitis, nasal polyp, and nasosinusitis; 3) cardiovascular comorbidity, including bradycardia and atrioventricular block; 4) cardiovascular treatment, including anti-hypertensive medications; 5) neurological comorbidity; 6) recent use of sedative and analgesic drugs and psychotropic medications; 7) allergy to an \(\alpha\)-adrenergic agonist; 8) alcohol abuse.

Patients were randomly divided into four groups: control (group C), intranasal dexmedetomidine 1 \(\mu\)g/kg (group IN1), intranasal dexmedetomidine 2 \(\mu\)g/kg (group IN2), and intravenous dexmedetomidine 1 \(\mu\)g/kg (group IV) group. Dexmedetomidine 1 \(\mu\)g/kg and 2 \(\mu\)g/kg were administered intranasally 40 min before anesthesia induction in groups IN1 and IN2, respectively. The initial concentration of dexmedetomidine was 100 \(\mu\)g/mL (Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu, China), and intranasal drug was diluted with normal saline to a final volume of 1.6 mL. Dexmedetomidine was sprayed into both nostrils (0.8 mL per nostril). Normal saline was administered intravenously 30 min following nasal medication. Dexmedetomidine 1 \(\mu\)g/kg was administered intravenously 10 min before anesthesia induction in group IV. The study drug was diluted with normal saline to a final volume of 15 mL and was administered over 10 min. Normal saline was administered intranasally 30 min before intravenous medication. In group C, patients received normal saline intranasally and intravenously according to the above method (Fig. 1).

No pre-anesthetic medication was given. After patients entered the operating room, nurse anesthetists were instructed to keep patients calm and to avoid unnecessary noise. An 18 G catheter was inserted in the forearm vein and Lactated Ringer’s...
solution was infused at 8 mL/kg/h. The study was initiated after heart rate, noninvasive blood pressure, electrocardiography, pulse oxygen saturation, and bispectral index (BIS) monitoring were carried out. Atropine 0.005 mg/kg was given at a heart rate (HR) <50 bpm; phenylephrine 0.5 μg/kg was given when mean arterial pressure (MAP) reached <80% of the baseline value following intranasal administration. The Observer’s Assessment of Alertness/Sedation (OAA/S) scores and BIS values were recorded before induction.

The commercial BIS-guided closed-loop target-controlled infusion (TCI) system (Slgo Medical Technology Co., Ltd., Beijing, China) of propofol was adopted for general anesthesia induction. This system integrates the BIS module (Aspect Medical Systems, Newton, MA, USA) for continuous BIS monitoring and Marsh pharmacokinetic parameters for the TCI of propofol. After entering patient information, such as age, weight and height, the initial plasma propofol concentrations of groups C, IN1, IN2, and IV were set at 4.0, 3.0, 2.0, and 2.0 μg/mL, respectively, with their target BIS values at 50±5. When the BIS values decreased below 75, the closed-loop TCI system was initiated for automatic adjustment of propofol concentrations based on the dynamic BIS values, maintaining the BIS values within the target range. In addition, the system provides a real-time display of the dynamic BIS values and calculates plasma and effect-site concentrations of propofol. When the BIS reached the target values, effect-site TCI of remifentanil (Yichang Hu- manwell Pharmaceutical Co., Ltd., Yichang, Hubei, China) was applied via a commercially available TCI pump (slgo CP-600; Slgo Medical Technology Co., Ltd., Beijing, China) using the Minto pharmacokinetic model and adopting a constant effect-site concentration of 3.0 ng/mL. Then, intravenous administration of rocuronium 0.6 mg/kg was carried out 2 min later, and endotracheal intubation was performed 1 min thereafter. The lungs were ventilated to maintain an end-tidal carbon dioxide partial pressure (PetCO₂) of 30–40 mm Hg with 100% oxygen. If HR fell below 50 bpm during anesthesia induction, atropine 0.005 mg/kg was administered intravenously; in case of MAP below 80% of the baseline value, phenylephrine 0.5 μg/kg was administered intravenously. These treatments were repeated as necessary. Upon induction completion, the TCI of remifentanil was discontinued temporarily while urinary catheterization, as well as skin sterilization and draping, were initiated.

All hysterectomy procedures were performed by the same surgical team. TCI of remifentanil was restored 3 min before skin incision, with the same effect-site concentration of 3.0 ng/mL. The BIS values were maintained at 50±5 by closed-loop TCI of propofol; intraoperative MAP was maintained at baseline value ±20% by remifentanil administration. With MAP below the preset range, TCI of remifentanil was terminated and restored when MAP reached the preset range, with the level obtained at that time set as the new effect-site concentration. If BP was over the preset range, the effect-site concentration was increased by 0.5 ng/mL every 3 min till the preset MAP range was reached. When strong surgical stimuli were triggered (for instance, at the moment of skin incision, abdomen approach, and surgical exploration) and the concentration of remifentanil was altered, MAP was measured every 1 min; otherwise, it was measured every 3 min. If intraoperative MAP reached the preset range with HR below 50 bpm, atropine 0.005 mg/kg was administered; however, with normal MAP and HR over 90 bpm, esmolol 0.5 mg/kg was given; these treatments were repeated as needed. Atracurium was administered to maintain muscle relaxation at a rate of 5 μg/kg/min and stopped before closing the abdomen. Prior to skin anastomosis, propofol and remifentanil were discontinued, while sufentanil 0.3 μg/kg and ramipril 0.3 mg were administered.

Patients were transferred to the postanesthesia care unit (PACU) for 5 hours of postoperative observation. Patients were wakened when BIS values were restored to 70 and administrated neostigmine 0.02 mg/kg and atropine 0.01 mg/kg to antagonize muscle relaxation if necessary. Tracheal extubation was preformed after patients could obey simple commands, raise their heads for more than 5 sec, and breathe deeply on request. Oxygen inhalation, vital sign monitoring, and pain assessment were conducted postoperatively for all patients. When visual analogue scale (VAS) exceeded 3, sufentanil 0.1 μg/kg was administered, repeatedly if necessary, till VAS reached ≤3. Afterwards, patients were given a patient-controlled intravenous analgesia delivery system with sufentanil 2.0 μg/kg diluted to 100 mL, 2.0 mL boluses with a 10-minute lockout interval without continuous infusion, to maintain VAS ≤3.

Random numbers were generated using the EXCEL random number generator and allocated to each patient. Then, patients were divided into four groups in numerical order. One anesthetist applied intravenous or intranasal dexmedetomidine administration, set the initial propofol target concentration according to grouping, and turned on or off the BIS-guided propofol TCI pump. Another anesthetist, who was blinded to patient grouping and propofol TCI pump, performed anesthesia following the study protocol. Another PACU anesthetist blinded to grouping was in charge of pain assessment and analgesic administration. The main outcome measures were effect-site concentration of propofol required to reach the target BIS value and total doses of propofol and remifentanil during anesthesia maintenance. Secondary outcome measures were time to first postoperative sufentanil supplement, postoperative total sufentanil dosage within 24 h, and number of patients that required atropine and phenylephrine during anesthesia induction.

**Sample size and statistical analysis**

Sample size calculation was based on the following assumptions: 1) The primary end point was propofol dosage required for maintenance of anesthesia. 2) In a previous study, the average infusion rate of propofol was 4.7±1.6 mg/kg/h in maintenance when using manual propofol and remifentanil TCI. 10 3)
Le Guen, et al.\(^{11}\) showed a 30% decrease of propofol requirements by a loading dose of 1 μg/kg dexmedetomidine followed by an infusion rate of 0.5 μg/kg/h during maintenance of anesthesia. We assumed that propofol requirements would be 20%, 20%, and 30% less in the present of intravenous dexmedetomidine 1 μg/kg and intranasal dexmedetomidine 1 and 2 μg/kg than without dexmedetomidine, respectively. 4 A two-tailed \(\alpha\) of 0.05 and \(\beta\) of 0.10 required a sample size of 26 subjects per group. We thus planned to enroll 120 subjects in this study.

Data were analyzed using the SPSS statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA) for Microsoft Windows. Data are expressed as means±SD or medians (with interquartile ranges, IQR) and numbers when appropriate. The significance level was set at 5% unless otherwise reported. Numerical variables were compared using parametric one-way ANOVA with least significant difference test for post hoc analysis or the nonparametric Kruskal-Wallis test followed by Mann-Whitney U with Bonferroni correction for between-group comparison after testing for normal distribution and homogeneity variance. The time to first sufentanil rescue was compared using a log-rank test with Bonferroni correction. Chi-square test and Fisher exact test were used for intergroup comparison of categorical data with Bonferroni correction. The significance level for Bonferroni correction was set at 0.0083.

**RESULTS**

One hundred and forty-four patients were screened for eligibility, and 120 were subsequently allocated to four groups. Eleven patients with hypertension, four patients with nasal diseases, and two patients with bradycardia were excluded. A total of one hundred and eight patients completed the study (Fig. 2).

There were no significant differences in patient characteristics, baseline MAP and HR, baseline BIS, operation time, intraoperative urine output, and blood loss (Table 1).

---

**Assess for eligibility** (n=144)
- Excluded (n=24)
  - Not meeting inclusion criteria (n=17)
  - Declined to participate (n=5)
  - Cancelled the surgical procedure (n=2)

**Randomized** (n=120)

**Allocated to control group** (n=30)
- Received allocated intervention (n=30)

**Discontinued intervention** (n=2)
Reason:
- Changed surgery mode in operation (n=1)
- Operation time exceed 2 h (n=1)

**Allocated to intranasal 1.0 μg·kg\(^{-1}\) DEX group** (n=30)
- Received allocated intervention (n=30)

**Discontinued intervention** (n=4)
Reason:
- Changed surgery mode in operation (n=2)
- Operation time exceed 2 h (n=2)

**Allocated to intranasal 2.0 μg·kg\(^{-1}\) DEX group** (n=30)
- Received allocated intervention (n=30)

**Discontinued intervention** (n=2)
Reason:
- Intraoperative blood loss volume more than 15% of systemic blood volume (n=1)
- Operation time exceed 2 h (n=1)

**Allocated to intravenous 1.0 μg·kg\(^{-1}\) DEX group** (n=30)
- Received allocated intervention (n=30)

**Discontinued intervention** (n=3)
Reason:
- Changed surgery mode in operation (n=1)
- Operation time exceed 2 h (n=1)

**Allocated to intravenous 2.0 μg·kg\(^{-1}\) DEX group** (n=30)
- Received allocated intervention (n=30)

**Discontinued intervention** (n=1)
- Operation time exceed 2 h (n=1)

**Analyzed** (n=27)
- Excluded from analysis (n=1)
  - Declined to complete study following surgery (n=1)

**Analyzed** (n=26)
- Excluded from analysis (n=0)

**Analyzed** (n=28)
- Excluded from analysis (n=0)

**Analyzed** (n=27)
- Excluded from analysis (n=0)

*Fig. 2. Trial consort diagram. DEX, dexmedetomidine.*
Dexmedetomidine significantly decreased BIS values and OAA/S scores at 40 min after intranasal administration. The BIS values and OAA/S scores were significantly lower in patients given intranasal dexmedetomidine 2 μg/kg than intranasal dexmedetomidine 1 μg/kg. There were no significant differences in adverse hemodynamics events before anesthesia induction between the groups (Table 2).

Anesthesia induction was quicker in groups IN2 and IV, compared to groups IN1 and C. The effect-site concentration of propofol for reaching target BIS values in groups IN1 and IN2 were significantly lower than that in control group. Patients given intravenous dexmedetomidine required significantly less propofol concentration than the same dose of intranasal dexmedetomidine for anesthetic induction and more propofol concentration than the double dose of intranasal dexmedetomidine. More patients in group IV required treatment with atropine than the other groups. No intergroup differences were observed for numbers of patients requiring phenylephrine (Table 3).

There were no significant differences in anesthesia maintenance time. Significantly less propofol were required in groups IN1 and IN2 than the control group in the maintenance phase. In addition, the dosage of propofol for maintaining the target BIS value in group IN2 was significantly lower than that in group IN1. Patients given intravenous dexmedetomidine required significantly less propofol dosage than intranasal dexmedetomidine for anesthesia maintenance at the same preoperative dose and more propofol dosage than the double dose of intranasal dexmedetomidine. Significantly less remifentanil was required in groups IN2 and IV than groups C and IN1 in the maintenance phase. There were no significant differences in remifentanil requirements between groups C and IN1 (Table 4).

There were no significant differences in postoperative extubation time. The median time to first postoperative rescue sufentanil was significantly longer in groups IN2 and IV than that in groups IN1 and C. No intergroup differences were observed for numbers of patients requiring rescue succinylcholine (Table 3).

### Table 1. Demographic Data and Perioperative Parameters

| Group          | Age (yrs) | Weight (kg) | Baseline MAP (mm Hg) | Baseline HR (bpm) | Baseline BIS | Operative time (min) | Intraoperative urine output (mL/h) | Blood loss (mL) |
|----------------|-----------|-------------|----------------------|-------------------|--------------|----------------------|------------------------------------|----------------|
| Group C (n=27) | 48±4      | 59±5        | 87±7                 | 77±10             | 97 (96–98)   | 103±15               | 133±39                             | 61±28          |
| Group IN1 (n=26)| 47±4      | 58±5        | 84±6                 | 81±7              | 96 (96–98)   | 99±15                | 128±34                             | 48±25          |
| Group IN2 (n=28)| 47±5      | 58±4        | 86±6                 | 81±9              | 97 (96–98)   | 102±12               | 153±46                             | 56±27          |
| Group IV (n=27)| 47±5      | 58±4        | 88±5                 | 79±10             | 97 (96–97)   | 97±14                | 145±44                             | 66±27          |

MAP, mean arterial pressure; HR, heart rate; BIS, bispectral index; IN1, intranasal dexmedetomidine 1 μg/kg; IN2, intranasal dexmedetomidine 2 μg/kg; IV, intravenous dexmedetomidine 1 μg/kg.

Data are mean±SD or median (interquartile ranges).

### Table 2. Effects on BIS and OAA/S and Hemodynamics of Intranasal and Intravenous Dexmedetomidine

| Group          | BIS values before induction | OAA/S scores before induction | Bradycardia requiring treatment | Hypotension requiring treatment |
|----------------|----------------------------|-------------------------------|---------------------------------|---------------------------------|
| Group C (n=27) | 96 (93–97)                 | 5 (5–5)                       | 1                               | 0                               |
| Group IN1 (n=26)| 90 (88–94)**              | 5 (4–5)*                      | 0                               | 0                               |
| Group IN2 (n=28)| 78 (73–84)**              | 4 (4–4)*                      | 4                               | 4                               |
| Group IV (n=27)| 84 (82–86)**               | 4 (4–5)**                     | 4                               | 4                               |

BIS, bispectral index; OAA/S, observer assessment of alertness/sedation; IN1, intranasal dexmedetomidine 1 μg/kg; IN2, intranasal dexmedetomidine 2 μg/kg; IV, intravenous dexmedetomidine 1 μg/kg.

Data are median (interquartile ranges) or number.

* p<0.0083 vs. group C, † p<0.0083 vs. group IN1, ‡ p<0.0083 vs. group IN2.

### Table 3. Induction Phase (from the Start of TCI Propofol to the End of TCI Remifentanil)

| Group          | Induction time (min) | Propofol concentration reaching preset BIS value (μg/mL) | Number of patients required atropine | Number of patients required phenylephrine |
|----------------|----------------------|---------------------------------------------------------|-------------------------------------|------------------------------------------|
| Group C (n=27) | 10.0 (9.0–11.0)      | 3.8 (3.8–4.0)                                          | 3                                   | 2                                        |
| Group IN1 (n=26)| 9.5 (7–11)          | 2.9 (2.6–3.0)*                                         | 2                                   | 1                                        |
| Group IN2 (n=28)| 8 (7–10)*           | 1.6 (1.4–2.1)*                                         | 3                                   | 2                                        |
| Group IV (n=27)| 8 (8–10)*           | 2.2 (1.7–2.4)*                                         | 12‡†‡                                 | 2‡†‡                                     |

TCI, target-controlled infusion; BIS, bispectral index; IN1, intranasal dexmedetomidine 1 μg/kg; IN2, intranasal dexmedetomidine 2 μg/kg; IV, intravenous dexmedetomidine 1 μg/kg.

Data are median (interquartile ranges) or number.

* p<0.0083 vs. group C, † p<0.0083 vs. group IN1, ‡ p<0.0083 vs. group IN2.
Table 4. Maintenance Phase (from Skin Incision to Termination of TCI Propofol and Remifentanil)

|                    | Group C (n=27) | Group IN1 (n=26) | Group IN2 (n=28) | Group IV (n=27) |
|--------------------|---------------|------------------|------------------|----------------|
| Maintenance time (min) | 98±15         | 95±15            | 98±11            | 93±14          |
| Propofol dosage (mg/kg/h) | 4.00 (3.77–4.32) | 3.70 (3.35–3.90)* | 2.70 (2.50–3.22)* | 3.30 (3.00–3.40)*† |
| Remifentanil dosage (μg/kg/min) | 0.15 (0.13–0.17) | 0.14 (0.13–0.18) | 0.11 (0.07–0.15)* | 0.11 (0.10–0.15)*† |

TCI, target-controlled infusion; IN1, intranasal dexmedetomidine 1 μg/kg; IN2, intranasal dexmedetomidine 2 μg/kg; IV, intravenous dexmedetomidine 1 μg/kg.

Data are mean±SD or median (interquartile ranges).

*p<0.0083 vs. group C, †p<0.0063 vs. group IN1, ††p<0.0083 vs. group IN2.

Table 5. Postoperative Phase

|                    | Group C (n=27) | Group IN1 (n=26) | Group IN2 (n=28) | Group IV (n=27) |
|--------------------|---------------|------------------|------------------|----------------|
| Extubation time (min) | 10±3          | 10±4             | 9±3              | 9±3            |
| Time to VAS >3 at rest (min) | 25 (15–50)    | 35 (20–65)       | 90 (65–100)*†   | 75 (45–95)*†   |
| Postoperative sufentanil requirements in the first 24 h (µg) | 76 (64–82)    | 57 (56–88)       | 45 (34–58)*†    | 56 (50–57)*†   |

VAS, visual analogue scale; IN1, intranasal dexmedetomidine 1 μg/kg; IN2, intranasal dexmedetomidine 2 μg/kg; IV, intravenous dexmedetomidine 1 μg/kg.

Data are mean±SD or median (interquartile ranges).

*p<0.0083 vs. group C, †p<0.0063 vs. group IN1, ††p<0.0083 vs. group IN2.

![Kaplan-Meier curves analyzing delay to first postoperative sufentanil rescue. DEX, dexmedetomidine.](http://dx.doi.org/10.3349/ymj.2016.57.4.998)

DISCUSSION

As shown above, intranasal administration of dexmedetomidine prior to anesthesia induction can reduce perioperative anesthetics requirements, and the effect of intranasal dexmedetomidine 1 μg/kg was less pronounced than that observed with the same dose of intravenous dexmedetomidine in adults.

Our study applied a BIS-guided, closed-loop TCI system, which automatically adjusts the target concentration of propofol to maintain target BIS values, making medication more objective, avoiding subjective influences from the operators, and realizing a smoother sedation depth. During induction and maintenance of anesthesia, intranasal dexmedetomidine attenuated propofol requirements for reaching predetermined BIS values in a dose-dependent manner, in accordance with previous findings focused on the sedative effect of intranasal dexmedetomidine in children. A study by Wang, et al.12 indicated intranasal dexmedetomidine 2 μg/kg induces a stronger sedative effect than 1 μg/kg in children. When dexmedetomidine was administered intranasally for procedural sedation in children undergoing diagnostic magnetic resonance imaging, the success rates of dexmedetomidine 2 μg/kg and 3 μg/kg were 60% and 86%, respectively.13,14

Previous studies indicated that intranasal and intravenous dexmedetomidine had similar pharmacological effects. Iirola, et al.15 applied both intranasal and intravenous dexmedetomidine to healthy volunteers and recorded their OAA/S scores and BIS values, finding similar areas under the curve for the OAA/S scores and BIS values within 3 h. In addition, Zhang, et al.6 demonstrated that OAA/S scores of patients receiving the same dose of dexmedetomidine intranasally and intravenously were not significantly different. As shown above, intravenous dexmedetomidine 1 μg/kg resulted in a lower dosage of propofol used during anesthesia induction and maintenance than those required with the same dose of intranasal dexmedetomidine, not corroborating the above studies. The following reasons may explain this inconsistency: first, dexmedetomidine has a unique conscious sedation effect, and it is hard to judge variations in the degree of sedation based on subjective OAA/S scores when sedation is not deep; patients need to be called and patted during OAA/S assessment, and these stimuli not only disturb the sedative state of healthy volunteers but also alter the BIS values. In addition, without muscle relaxants, BIS monitoring is easily disturbed by electromyography of the frontalis muscle.14 Here, we adjusted propofol dosages based on in-
Dexmedetomidine has central anti-sympathetic and vagal nervous activity promoting effects, which may result in hypotension and bradycardia, in particular at high doses. We found that more patients required atropine injections following intravenous dexmedetomidine 1.0 μg/kg; meanwhile, Wang, et al. also demonstrated that intravenous dexmedetomidine 1.0 μg/kg during TCI of propofol increases the incidence of bradycardia. However, intranasal administration of dexmedetomidine did not increase atropine requirements during anesthesia induction, which may be associated with slower absorption and lower peak concentration with intranasal administration, compared with the intravenous treatment. There are mainly two possible reasons why intravenous and intranasal dexmedetomidine do not increase vasopressors requirements. First, dexmedetomidine has a bidirectional effect upon blood pressure: when exerting an effect upon the peripheral α2 adrenoceptor, the drug will contract peripheral blood vessels and increase blood pressure. Therefore, even an intravenous load of 1.0 μg/kg dexmedetomidine will not increase the usage rate of vasopressors. Second, because propofol induces a dose-dependent decrease in blood pressure, its reduced usage induced by dexmedetomidine can compensate for the hypotension caused by the latter drug.

Dexmedetomidine produces characteristically arousable sedation, which differs markedly from other sedatives. Kasuya, et al. showed that at comparable BIS values, OAA/S scores were higher with dexmedetomidine than with propofol sedation. Although the median (range) of BIS was 78 (69–93) with intranasal dexmedetomidine 2 μg/kg, the median (range) of OAA/S was 4 (4–5), which is considered a shallow sedation level. In the study, the sedative level and hemodynamics parameter were recorded merely 40 min following intranasal dexmedetomidine. Further investigation was needed to explore pharmacological effect of intranasal dexmedetomidine 2 μg/kg.

Onset of intranasal dexmedetomidine is delayed compared with that of intravenous treatment, which limits its application in anesthesia, particularly during consecutive operations. In the current study, we did not emphatically compare differences in onset time between intranasal dexmedetomidine 1 and 2 μg/kg. Previous studies on children showed the onset time of sedation following intranasal administration of 1 μg/kg dexmedetomidine was 25 min, whereas the onset time of intranasal dexmedetomidine 2 and 2.5 μg/kg shortened to 15 and 13.4 min, respectively. We, therefore, speculate that the onset time of sedation of intranasal dexmedetomidine 2 μg/kg may be shortened in adults, although this still requires further verification.

In conclusion, both intranasal and intravenous administrations of dexmedetomidine reduced perioperative anesthetic requirements. Intranasal treatment, however, resulted in a less pronounced effect at the same dose of 1 μg/kg. Preoperatively, intranasal dexmedetomidine 2 μg/kg produces a more obvious anesthetics-sparing effect and seems to not increase the incidence of bradycardia and hypotension in adults.
REFERENCES

1. Kaur M, Singh PM. Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesth Essays Res 2011;5:128-33.
2. Arcangelì A, D’Alò C, Gaspari R. Dexmedetomidine use in general anesthesia. Curr Drug Targets 2009;10:687-95.
3. Grassini-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc Lj, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther 2012;134:366-79.
4. Jia J, Chen JY, Hu X, Li WX. A randomised study of intranasal dexmedetomidine and oral ketamine for premedication in children. Anaesthesia 2013;68:944-9.
5. Ghali AM, Mahfouz AK, Al-Bahrani M. Preanaesthetic medication in children: a comparison of intranasal dexmedetomidine versus oral midazolam. Saudi J Anaesth 2011;5:387-91.
6. Cheung CW, Ng KF, Liu J, Yuen MY, Ho MH, Irwin MG. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia. Br J Anaesth 2011;107:430-7.
7. Cheung CW, Qiu Q, Liu J, Chu KM, Irwin MG. Intranasal dexmedetomidine for patient-controlled sedation during upper gastrointestinal endoscopy: a randomised trial. Acta Anaesthesiol Scand 2015;59:215-23.
8. Zhang X, Bai X, Zhang Q, Wang X, Lu L. The safety and efficacy of intranasal dexmedetomidine during electrochemistry for facial vascular malformation: a double-blind, randomized clinical trial. J Oral Maxillofac Surg 2013;71:1835-42.
9. Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg 2007;105:374-80.
10. Liu N, Chazot T, Hamada S, Landais A, Boichut N, Dussaussoy C, et al. Closed-loop coadministration of propofol and remifentanil guided by bispectral index: a randomized multicenter study. Anesth Analg 2011;112:546-57.
11. Le Guen M, Liu N, Tournou E, Augé M, Tuil O, Chazot T, et al. Dexmedetomidine reduces propofol and remifentanil requirements during bispectral index-guided closed-loop anaesthesia: a double-blind, placebo-controlled trial. Anesth Analg 2014;118:946-55.
12. Wang SS, Zhang MZ, Sun Y, Wu C, Xu WY, Bai J, et al. The sedative effects and the attenuation of cardiovascular and arousal responses during anesthesia induction and intubation in pediatric patients: a randomized comparison between two different doses of preoperative intranasal dexmedetomidine. Paediatr Anaesth 2014;24:275-81.
13. Ambi US, Joshi C, Ganeshnavar A, Adarsh E. Intranasal dexmedetomidine for paediatric sedation for diagnostic magnetic resonance imaging studies. Indian J Anaesth 2012;56:587-8.
14. Ibrahim M. A prospective, randomized, double blinded comparison of intranasal dexmedetomidine vs intranasal ketamine in combination with intravenous midazolam for procedural sedation in school aged children undergoing MRI. Anesth Essays Res 2014;8:179-86.
15. iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, et al. Bioavailability of dexmedetomidine after intranasal administration. Eur J Clin Pharmacol 2011;67:825-31.
16. Vivien B, Di Maria S, Quattara A, Langeron O, Coriat P, Riou B. Overestimation of Bispectral Index in sedated intensive care unit patients revealed by administration of muscle relaxant. Anesthesiology 2003;99:9-17.
17. Nguyen Van NE, Anderson J, Hoemscenmeyer DG, Tobias JD. Effects of dexmedetomidine on propofol and remifentanil infusion rates during total intravenous anesthesia for spine surgery in adolescents. Paediatr Anaesth 2008;18:1190-5.
18. Bekker A, Sturaitis M, Bloom M, Morig M, Golfinos J, Parker E, et al. The effect of dexmedetomidine on perioperative hemodynamics in patients undergoing craniotomy. Anesth Analg 2008;107:1307-7.
19. Angst MS, Ramaswamy B, Davies MF, Maze M. Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine andalfentanil in humans. Anesthesiology 2004;101:744-52.
20. Khan ZP, Ferguson CN, Jones RM. alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia 1999;54:146-65.
21. Wu X, Hang LH, Chen YE, Wang H, Shao DH, Chen Z. Remifentanil requirements for preventing motor response to skin incision in healthy women anesthetized with combinations of propofol and dexmedetomidine titrated to similar Bispectral Index (BIS) values. Ir J Med Sci 2015;184:805-11.
22. Gurbet A, Basagaan-Mogol E, Turkler G, Ugun E, Kaya FN, Ozcan B. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Can J Anaesth 2006;53:646-52.
23. Al-Zaben KR, Quailasat IF, Al-Ghanem SM, Massad IM, Al-Mutsa MM, Al-Oveidi AS, et al. Intraoperative administration of dexmedetomidine reduces the analgesic requirements for children undergoing hypospadia surgery. Eur J Anaesthesiol 2010;27:247-52.
24. Unlugenc H, Gunduz M, Guler T, Yagmur O, Isik G. The effect of pre-anesthetic administration of intravenous dexmedetomidine on postoperative pain in patients receiving patient-controlled morphine. Eur J Anaesthesiol 2005;22:386-91.
25. Wang T, Ge S, Xiong W, Zhou P, Cang J, Xue Z. Effects of different loading doses of dexmedetomidine on bispectral index under stepwise propofol target-controlled infusion. Pharmacology 2013;91:1-6.
26. Kasuya Y, Govinda R, Rauch S, Mascha EJ, Sessler DJ, Turan A. The correlation between bispectral index and observational sedation scale in volunteers sedated with dexmedetomidine and propofol. Anesth Analg 2009;109:1811-5.
27. Yuen VM, Hui TW, Irwin MG, Yao TJ, Wong GL, Yuen MK. Optimal timing for the administration of intranasal dexmedetomidine for premedication in children. Anaesthesia 2010;65:922-9.
28. Talon MD, Woodson LC, Sherwood ER, Aarsland A, McRae L, Benham T. Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. J Burn Care Res 2009;30:599-605.
29. Mekitarian Filho E, Robinson F, de Carvalho WB, Gilio AE, Maze M. The safety and efficacy of intranasal dexmedetomidine on sedation for pediatric computed tomography imaging. J Pediatr 2015;166:1313-5.e1.